The U.S. Food and Drug direction today exercised its new control under the Food and Drug management Amendments Act of 2007 (FDAAA) to require manufacturers of "conventional" antipsychotic drugs to make safety-related changes to prescribing information, or labeling, to warn about an increased risk of death customer's broker with the off-label use of these drugs to treat behavioral problems in older people with dementia.

More: - Brought to my attention by